Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

Fluvoxamine (maleate)

  • Zoom
    Fluvoxamine (maleate)
  • Fluvoxamine (maleate)
Cat No: 15617
Biochemicals - Ion Channel Modulation
Cayman

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI).{63221} It selectively inhibits reuptake of serotonin over norepinephrine reuptake in rat hypothalamic synaptosomes (Kis = 6.2 and 1,100 nM, respectively). Fluvoxamine (10 mg/kg) reduces i...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-aminoethyl)oxime, 2Z-butenedioate
Correlated keywords:
  • 54739-?20-?7 54739-18-3 Avoksin Avoxin Depromel DU23000 Dumirox Faverin Faverine Fevarin Floxyfral Luvox Maveral MK264 NSC309469 sigma1
Product Overview:
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI).{63221} It selectively inhibits reuptake of serotonin over norepinephrine reuptake in rat hypothalamic synaptosomes (Kis = 6.2 and 1,100 nM, respectively). Fluvoxamine (10 mg/kg) reduces immobility time in the forced swim test in mice, an effect that can be blocked by the sigma-1 (σ1) receptor antagonist BD 1047 (Item No. 22928).{63222} It also reduces marble-burying behavior in the marble-burying test in mice when administered at a dose of 45 mg/kg, indicating anxiolytic- or reduced obsessive compulsive-like behaviors.{63223} Formulations containing fluvoxamine have been used in the treatment of obsessive compulsive disorder and social anxiety disorder.
Size 10 mg
Shipping dry ice
CAS Number 61718-82-9
Molecular Formula C15H21F3N2O2 • C4H4O4
SMILES COCCCC/C(C1=CC=C(C(F)(F)F)C=C1)=N\OCCN.OC(/C=C\C(O)=O)=O
Molecular Weight 434,4
Formulation A crystalline solid
Purity ≥95%
Custom Code 2922.19
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

Search